08:00 , Jan 10, 2005 |  BC Week In Review  |  Company News

University of Pittsburgh Cancer Institute other research news

Researchers published in Science that, in cultured oral cancer cells, dynein helps cells with more than 2 centrosomes to avoid abnormal division by clustering. Researchers also found that the overexpression of another protein, NuMa, inhibits...
07:00 , May 26, 1998 |  BC Week In Review  |  Clinical News

Matritech regulatory update

The FDA said NMPS's NuMA Test Kit for colon cancer does not meet the criteria for 510 (k) marketing clearance. NMPS is continuing discussions with the FDA and is in ongoing studies to support a...
07:00 , May 26, 1998 |  BioCentury  |  Finance

Froth, not momentum

Froth, not momentum Recent stock surges such as EntreMed (ENMD), NeoTherapeutics (NEOT) and Progen (PGLAF) may raise hopes that momentum players are starting to play in the sector. But Street watchers note that the big...
08:00 , Mar 2, 1998 |  BC Week In Review  |  Clinical News

NuMA test of nuclear matrix protein in blood data

NMPS announced that data on 85 patients from its 501(k) submission of its NuMA test kit show better sensitivity for detecting colon cancer as compared to carcino-embryonic antigen (CEA) testing. A blinded analysis of banked...
07:00 , Oct 20, 1997 |  BC Week In Review  |  Clinical News

Matritech regulatory update

NMPS submitted a 510(k) application to the FDA for clearance of NMPS's NuMA Test Kit, a blood-based diagnostic that measures levels of nuclear matrix proteins, which are elevated in colon cancer. Matritech Inc. (NMPS), Newton,...
07:00 , May 12, 1997 |  BC Week In Review  |  Clinical News

Matritech regulatory update

NMPS received notices of allowance on two U.S. patents covering mitotic apparatus protein (NuMA), a structural component of the cell nucleus that is released by dying cells and expressed in relatively large amounts by cancerous...
07:00 , Oct 2, 1995 |  BC Week In Review  |  Company News

Matritech other research news

The Cambridge, Mass., company received a $93,000 Phase I SBIR from the National Cancer Institute to develop an assay to screen for cancer compounds using NuMA. NMPS said that NuMA is over-expressed in cancer cells...
07:00 , May 15, 1995 |  BC Week In Review  |  Company News

Matritech sales and marketing update

Toray-Fuji Bionics (Tokyo) will distribute in Japan NMPS's Matri-tect NMP41 Cell Death Test Kit, an enzyme immunoassay used to quantitate human cell death in serum and cell-culture supernatants. The kit is specific for a human...